Development and Characterization of Solid Dispersion-Based Oral Formulations of Febuxostat for Improved Dissolution and Release Performance: A Review

References

[1] Alghaith AF, Mahdi WA, Haq N, Alshehri S, Shakeel F. Solubility and thermodynamic properties of febuxostat in mono-solvents at different temperatures. Materials. 2022;15(20):7318.

[2] Aulton ME, Taylor KMG. Aulton's pharmaceutics: the design and manufacture of medicines. London: Elsevier; 2018.

[3] Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281–1302.

[4] Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231(2):131–144.

[5] Dixit RP, Puthli SP. Oral drug delivery by solid dispersion: a review. Indian J Pharm Sci. 2009;71(6):595–601.

[6] Doppalapudi S. Formulation and evaluation of solid dispersion of febuxostat by fusion method. Int J Pharm Sci Res. 2019;10(4):1785–1793.

[7] U.S. Food and Drug Administration. Uloric (febuxostat) tablets: prescribing information. Rockville (MD): FDA; 2017.

[8] Gupta MK, Vanwert A, Bogner RH. Formation of physically stable amorphous drugs by milling with polymers. J Pharm Sci. 2003;92(3):536–551.

[9] Jadhav NR, Gaikwad VL, Nair KJ, Kadam HM. Solid dispersion: solubility enhancement technique. J Pharm Res. 2011;4(3):847–852.

[10] Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47–60.

[11] MedCrave. Solid dispersions: a technology for improving bioavailability. J Anal Pharm Res. 2019;8(2):42–48.

[12] Nikghalb LA, Singh G, Singh G, Kahkeshan KF. Solid dispersion: methods and polymers to increase solubility. J Appl Pharm Sci. 2012;2(10):170–175.

[13] Patel A, Patel V. Optimization of amorphous solid dispersion techniques for febuxostat. Int J Pharm Sci Rev Res. 2021;66(1):45–52.

[14] Patel VP, Shah A, Desai S. Formulation and optimization of febuxostat solid dispersions. Int J Pharm Investig. 2021;11(2):125–134.

[15] National Center for Biotechnology Information. PubChem Compound Summary for Febuxostat. Bethesda (MD): National Library of Medicine; 2024.

[16] Sareen S, Mathew G, Joseph L. Improvement in solubility of poorly water-soluble drugs by solid dispersion. J Pharm Investig. 2012;42(1):1–13.

[17] Sheng X, Chen J, Li J, et al. Enhancement of dissolution and bioavailability of febuxostat by solid dispersion. Colloids Surf B Biointerfaces. 2018;172:422–430.

[18] Sohn JS, Kim JH, Lee SH, et al. Development and evaluation of febuxostat solid dispersion through a screening method. Pharmaceutics. 2023;15(3):812.

[19] Sohn JS, Park JH, Kim YJ, et al. Febuxostat solubilization and stabilization using Kolliphor HS-15 and chitosan. Carbohydr Polym. 2023;312:120809.

[20] Tang J, Sun J, Liu Y, et al. Preparation and evaluation of febuxostat solid dispersion. Drug Dev Ind Pharm. 2018;44(10):1584–1592.

[21] Tekade AR, Yadav JN. A review on solid dispersion and carriers. Curr Drug Deliv. 2020;17(3):219–235.

[22] United States Pharmacopeial Convention. United States Pharmacopeia–National Formulary (USP-NF). Rockville (MD): USP Convention; 2023.

[23] Vasconcelos T, Sarmento B, Costa P. Solid dispersions as a strategy to improve oral bioavailability of poorly water-soluble drugs. Drug Discov Today. 2007;12(23–24):1068–1075.

[24] Vimalson D, Ramasamy V, Manivannan R. Solid dispersion technique to enhance solubility of febuxostat. Asian J Pharm. 2019;13(3):345–352.

[25] Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19(7):921–925.

[26] Zhang XR, Zhao YP, Chen X. Simultaneous enhancement of solubility and dissolution rate of febuxostat. J Pharm Sci. 2017;106(11):3150–3158.

[27] Zhou Q, Li Y, Zhang Y. Amorphous solid dispersion systems: theory and applications. Asian J Pharm Sci. 2018;13(1):1–14.

[28] Patel VP, Patel AP. Amorphous solid dispersion techniques for febuxostat: a review. Folia Med. 2021;63(4):491–500.

[29] GSC Online Press. Solid dispersion systems for poorly soluble drugs. GSC Biol Pharm Sci. 2022;18(1):122–135.

[30] Yadav PS, Kumar V, Singh UP. Solid dispersion technology: a review. Int J Pharm Life Sci. 2011;2(9):1078–1095.

@article{1722290,
      author = {Vinit Kumar, Vinod Kumar Singh},
      title = {Development and Characterization of Solid Dispersion-Based Oral Formulations of Febuxostat for Improved Dissolution and Release Performance: A Review},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {2},
      pages = {1154-1171},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1722290.pdf},
      abstract = {Poor aqueous solubility is among the most persistent obstacles in oral drug development, since a large fraction of contemporary drug candidates dissolve too slowly to be reliably absorbed. Febuxostat, a non-purine selective xanthine-oxidase inhibitor used in the chronic management of gout and hyperuricaemia, exemplifies this problem: it is a Biopharmaceutics Classification System (BCS) Class II compound that combines high intestinal permeability with very low aqueous solubility, so its absorption is dissolution-rate limited and its bioavailability can be variable. This review examines the rationale, scientific principles, formulation strategies, and characterization framework for solid dispersion-based oral formulations designed to improve the dissolution and release performance of febuxostat. The molecular and physicochemical profile of the drug—its weakly acidic, pH-dependent solubility and its tendency to polymorphism—is related to the mechanisms by which solid dispersions enhance dissolution, namely reduction of crystallinity, conversion to the amorphous state, increased surface area, improved wettability, and the generation and maintenance of supersaturation. The principal hydrophilic carriers used in such systems, including polyvinylpyrrolidone (PVP K30), polyethylene glycol (PEG 6000), hydroxypropyl methylcellulose (HPMC), and Soluplus, are reviewed alongside the main preparation techniques—solvent evaporation, fusion, hot-melt extrusion, spray drying, freeze drying, and co-precipitation—and their comparative merits. The solid-state and dissolution characterization framework (FTIR, DSC, PXRD, SEM, and in-vitro dissolution) and the central problem of physical stability against recrystallization are discussed. The evidence indicates that a rationally selected carrier and preparation method can convert crystalline febuxostat into a stable amorphous dispersion that markedly accelerates dissolution and improves release consistency, providing a sound and scalable basis for enhanced oral delivery of this and other BCS Class II drugs.},
      keywords = {Febuxostat, Solid Dispersion, Dissolution Enhancement, BCS Class II Drug, Amorphous Formulation, Hydrophilic Polymers, Supersaturation, Solvent Evaporation, Hot-Melt Extrusion, In-Vitro Release, Oral Drug Delivery.},
      month = {August},
      doi = {https://doi.org/10.64388/IREV10I2-1722290}
  }